There was a time when not much was known about fibromyalgia or chronic fatigue syndrome. At first it was dismissed as either the yuppie flu, or the “illness of the 90’s”, or simply treated as arthritis or fibrositis, myalgia or a small number of conditions, however, over the last several years some advanced clinical research into these illnesses have yielded some incredible results.
Medical science has determined that genetic factors are involved, and much of this research has lead to the patent office to get specific new drugs available as approved for use in these conditions.
In the past, doctors didn’t know how to treat these illnesses, or even what was causing the patients symptoms. The patient looked fine, there were no diagnostics tests that revealed any underlying cause of their symptoms. These were trying times for both physician and patient alike.
Today, existing research has made available not only a much greater understanding of these conditions, but has lead to new drugs specifically for these illnesses that will be available in the near future.
Dr. Daniel Clauw, at University of Michigan Medical Center tells FMS Global News that “it is likely that in the next few years that there will be 3 – 4 drugs specifically approved for fibromyalgia – now there are none.
With some modest training, most health care providers can easily diagnose fibromyalgia. It’s treating it that they often struggle with, and the new drugs as well as education campaigns that will accompany the drugs, will be very helpful in this regard.”
Dr. Clauw is Professor of Rheumatology at University of Michigan, and a well known pioneer in fibromyalgia clinical research. Additional research is being done in Canada, and the UK.
Looking to the future, diagnosing and treating these life changing, and life altaring illnesses, may be more managable for both the patient and the physician.
FMS Global News is prepared to interview these drug companies and bring you a special report on our findings.